March 18, 2019 10:51 AM EDT
News Briefing

Aim­mune wins 12-month re­view and ad­com for peanut al­ler­gy drug; Phase­Bio flies on ear­ly da­ta for Bril­in­ta re­ver­sal agent

Natalie Grover

Reporter

→ Af­ter out­go­ing FDA com­mis­sion­er Scott Got­tlieb threw a span­ner in the works ear­li­er this year for peanut al­ler­gy drug de­vel­op­ers — Aim­mune $AIMT and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

Te­va launch­es Ste­lara biosim­i­lar at 85% dis­count as wider field emerges

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times